- Among individuals with chronic kidney disease, those who slept 7 hours/day had higher health-related quality of life than those who slept ≤5 hours/day or ≥9 hours/day.
Sleep disorders are prevalent in patients with chronic kidney disease.
Newswise — Washington, DC (May 3, 2018) — A new study indicates that sleep duration may influence the health-related quality of life (HRQOL) experienced by individuals with chronic kidney disease (CKD). The findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).
In patients with CKD, fatigue, lack of energy, and drowsiness are the most common symptoms that result in poor health-related quality of life (HRQOL), a patient’s comprehensive perception of physical and mental health. To examine whether sleep duration may affect HRQOL in individuals with CKD, Kyu-Beck Lee, MD (Sungkyunkwan University School of Medicine, Seoul, Korea) and colleagues examined data from 1910 adults in the Korean Cohort Study for Outcome in Patients with CKD (KNOW-CKD), a study designed to identify risk factors related to CKD and its outcomes.
The team found that 7-hour sleepers had the highest HRQOL, based on survey scores. There was an inverted U-shaped relationship between sleep duration and HRQOL so that those who slept ≤5 hours/day or ≥9 hours/day had lower HRQOL.
“Our findings suggest that short or long sleep duration is independently associated with low HRQOL in adults with CKD. Sleep duration is an important predictor of HRQOL in CKD,” said Dr. Lee. Additional studies are needed to determine whether promoting optimal sleep among patients may improve their health outcomes.
Study co-authors include Su-Ah Sung, Young Youl Hyun, Hayne Cho Park, Wookyung Chung, Yeong Hoon Kim, Yong-Soo Kim, Sue Kyung Park, Kook-Hwan Oh, and Curie Ahn, on behalf of the KNOW-CKD Study investigators.
Disclosures: The authors reported no financial disclosures.
The article, entitled “Sleep Duration and Health-Related Quality of Life in
Predialysis CKD—KNOW-CKD Study,” will appear online at http://cjasn.asnjournals.org/ on May 3, 2018, doi: 10.2215/CJN.11351017.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 18,000 members representing 112 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.
# # #